Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.

Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.

Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.

Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.

Abstract: The present invention relates to pharmacogenetics, more specifically to strategies involving biomarkers associated with the clinical response to a compound before or during treatment of a cartilage disorder, such as osteoarthritis. The present invention more particularly relates to the combination of JSW measurements and level of specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used in strategies such as patients' enrichment in clinical trials, patients' selection strategy before or during treatment or for adapting the treatment of a patient in the frame of treatments for cartilage disorder, such as osteoarthritis.

Abstract: A method performed by a vehicle system for handling parameters associated with surroundings of a vehicle. The vehicle system obtains information indicating a first parameter associated with the surroundings of the vehicle and sensed by at least one low power sensor. The low power sensor is associated with the vehicle. The vehicle system triggers startup of at least one high power sensor when the first parameter has fulfilled a criteria. The high power sensor consumes a larger amount of power than the low power sensor, and the high power sensor is associated with the vehicle or another vehicle. The vehicle system obtains information indicating at least a second parameter associated with the surroundings of the vehicle and sensed by the high power sensor.

Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.

Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.

Abstract: A method performed by a vehicle system for handling parameters associated with surroundings of a vehicle. The vehicle system obtains information indicating a first parameter associated with the surroundings of the vehicle and sensed by at least one low power sensor. The low power sensor is associated with the vehicle. The vehicle system triggers startup of at least one high power sensor when the first parameter has fulfilled a criteria. The high power sensor consumes a larger amount of power than the low power sensor, and the high power sensor is associated with the vehicle or another vehicle. The vehicle system obtains information indicating at least a second parameter associated with the surroundings of the vehicle and sensed by the high power sensor.

Abstract: Provided is a method of bioassay for the quantification of N- or C-terminal neo-epitope biomarkers formed by cleavage of a CRP, ApoE, lumican, versican, perlecan, decorin, biglycan or elastin by a proteinase. The method includes contacting a biofluid sample with an antibody reactive with the neo-epitope biomarker and determining the level of binding of the antibody to the biomarker in the sample. The assay is predictive of risk of cardiovascular disease events.

Abstract: Provided is a method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a protein of an atherosclerotic plaque such as lumican, versican, perlecan, deocrin, biglycan, collagen type III, CRP, ApoE, or elastin by a proteinase. The method comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of the immunological binding partner to peptide fragments in the sample. The assay is predictive of risk of cardiovascular disease events.

Abstract: A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a protein of an atherosclerotic plaque such as lumican, versican, perlecan, decorin, biglycan, collagen type III, CRP, ApoE, or elastin, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.

Abstract: The present invention encompasses genetically modified non-human mammals comprising a genetic modification that inhibits and/or reduces BRD1 activity in one or more tissue or cell, methods of producing the same, methods and uses for identifying compounds for treating a mental disorder and pharmaceutical formulations of said compounds.

Abstract: Excessive articular cartilage degradation is treated or prevented by administration to a mammal such as a human Pueraria lobata (Kudzu) root or an extract thereof.

Abstract: A method of immunoassay for fragments of a protein such as type II collagen in a biological sample detects fragments having a first epitope containing an isomerised amino acid residue and a second epitope generated by cleavage of the protein by the use of respective antibodies binding each of the two epitopes.

Abstract: A method of assay to determine the extent of collagen type II resorption activity comprising measuring the level of fragments of collagen type II that contain a cathepsin K generated neo-epitope not shared by collagen type I by binding the neo-epitope with an antibody specific for the neo-epitope and detecting the level of binding of said binding partner.

Abstract: A method of assay measuring in a biological sample fragments of a protein that contain an N-terminal neo-epitope and a C-terminal neo-epitope, each generated by protease cleavage of said protein, comprises binding the N-terminal neo-epitope with a first specific antibody and binding the C-terminal neo-epitope with a second specific antibody, and detecting the extent of dual binding of said antibodies.

Abstract: A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a protein of an atherosclerotic plaque such as lumican, versican, perlecan, decorin, biglycan, collagen type III, CRP, ApoE, or elastin, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.

Abstract: A method of diagnosis of cardiovascular disease (CVD) an immunoassay to measure aggrecan fragments in said sample, and association of an elevation above a normal level with the presence of CVD, is conducted by contacting aggrecan fragments in said sample with an first antibody reactive with an N-terminal first epitope formed by cleavage of aggrecan by a proteinase and with a second antibody reactive with a second aggrecan epitope which is present in aggrecan at a location in the C-terminal direction from the location of said N-terminal epitope, and measuring the extent of simultaneous binding of both antibodies.

Abstract: An immunoassay for aggrecan and/or aggrecan derived fragments comprises contacting a sample with an immunological binding partner which has specific binding affinity for the G2 domain of aggrecan at least when bearing keratan sulphate chains, and determining the existence or amount of specific binding of the immunological binding partner, which may be conducted as a sandwich assay using a first antibody that binds an N-terminal amino acid sequence comprising FFGVG . . . and a second antibody that binds an N-terminal amino acid sequence comprising ARGS.